Clinical trial

Treatment of Alzheimer's Disease With CX516 (Ampalex)

NCT00001662

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention CX516 (Ampalex) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Treatment of Alzheimer's Disease With CX516 (Ampalex)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date1996-12-01

PhasePHASE2

Conditions

Alzheimer's Diseaseverified · MONDO: Alzheimer disease

Dementiaverified · MONDO: dementia

Interventions

CX516 (Ampalex)DRUG

Sponsors & collaborators

National Institute of Neurological Disorders and Stroke (NINDS)lead sponsor

Mapped research locations

BethesdaMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00001662 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.